ARQ 531 also potently inhibits BTK and previously demonstrated a remarkable survival advantage in two immunocompetent adoptive transfer mouse models of CLL, Eμ-TCL1, and Eμ-MYC/TCL1 when compared with ibrutinib [36] resulting in a phase 1 dose escalation clinical trial in relapsed or refractory CLL [37]. This evidence concerns the gene MYC and B-cell chronic lymphocytic leukemia.